证券代码：600332 证券简称：白云山 公告编号：2025-097 广州白云山医药集团股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 647 | | --- | --- | | 其中：A 股股东人数 | 646 | | 境外上市外资股股东人数（H 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 873,410,148 | | 其中：A 股股东持有股份总数 | 838,588,017 | | 境外上市外资股股东持有股份总数（H 股） | 34,822,131 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 53.722168 | (一) 股东会召开的时间：2025 年 12 月 30 日 (二) 股东会召开的地点：广东省广州市荔湾区沙面北街 45 号本公司会议室 (三) 出席会议的普通股股东和恢 ...

二〇二五年十二月 北京市中伦（广州）律师事务所 关于广州白云山医药集团股份有限公司 2025 年第三次临时股东会的 法律意见书 北京市中伦（广州）律师事务所 关于广州白云山医药集团股份有限公司 2025 年第三次临时股东会的 法律意见书 致：广州白云山医药集团股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州白云山医药 集团股份有限公司（以下简称"公司"）委托，指派刘子丰律师和曾道扬律师（以 下简称"本所律师"）对公司 2025 年第三次临时股东会（以下简称"本次股东会"） 的合法性进行见证并出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"） ...

Key Points - The article discusses significant events in the private equity fund market from December 22 to December 28, highlighting the establishment of various government-guided and market-oriented funds across different regions in China [5]. Government-Guided Funds - Guangdong Province has established a strategic emerging industry investment fund with a registered capital of 50 billion RMB, focusing on private equity investments and asset management [7]. - A 20 billion RMB Hubei social security innovation fund has been signed, targeting sectors like optoelectronic information and automotive manufacturing [8]. - Beijing's Fengtai District has set up a government industry investment fund matrix with an initial scale of at least 10 billion RMB, focusing on AI, healthcare, and aerospace [8]. - The Shanghai Jiao Tong University Future Industry Mother Fund Phase II has been launched with an expected scale of 1 billion RMB, aimed at technology transfer and alumni entrepreneurship [9]. Market-Oriented Funds - The Dongguan Industry Chain Development Mother Fund has initiated the selection of sub-fund management institutions, with a total scale of 1.5 billion RMB, focusing on AI, semiconductors, and high-end manufacturing [10]. - Two private equity funds in Taizhou, Zhejiang, have been registered with a total scale of 2 billion RMB, focusing on traditional industry upgrades and strategic emerging industries [11]. - The Nanjing Aerospace Mother Fund plans to invest in a 1.5 billion RMB sub-fund, focusing on commercial aerospace and advanced manufacturing [12]. - The Henan Angel Mother Fund has completed registration with an initial scale of 1 billion RMB, aimed at supporting seed and early-stage projects [13]. Sector-Specific Funds - A 5 billion RMB biotechnology sub-fund has been established in Xiong'an, focusing on innovative drugs and high-end medical devices [14]. - The Jiangsu Social Security Innovation Fund has a first-phase scale of 500 billion RMB, targeting advanced manufacturing and AI [17]. - The Commercial Aerospace Industry Alliance Science and Technology Fund has been launched with an initial scale of 1 to 2 billion RMB, focusing on low-orbit satellites and reusable launch vehicles [18]. - The Chengdu High-tech Zone has established a 3 billion RMB venture capital mother fund, focusing on transportation, clean energy, and advanced manufacturing [21]. Collaborative Initiatives - The Henan Province New Materials Investment Fund is being set up in collaboration with local governments and listed companies to promote the new materials industry [15]. - The Guangdong Province AI and Robotics Industry Sub-Fund Cluster has been initiated with a first phase of 3 billion RMB, focusing on AI core algorithms and smart terminal applications [20]. - The first commercial aerospace socialized special fund has been established in Beijing with an initial scale of 2 billion RMB, targeting high-growth startups in the aerospace sector [21].

Key Points - Guizhou Moutai's controlling shareholder, Moutai Group, has completed a share buyback plan, acquiring 2,071,359 shares for a total of 3 billion yuan, increasing its stake to 56.63% of the total share capital [1] - Juneyao Airlines plans to purchase 25 Airbus A320 series aircraft for a total of 4.1 billion USD, with deliveries scheduled between 2028 and 2032 [1] - ST Panda is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [1] - Huali Co. has terminated its plan to acquire a 51% stake in Zhongke Huilian due to a lack of consensus on key transaction terms [1][2] - China Duty Free Group's subsidiary has signed a contract for a duty-free project at Beijing Capital International Airport, covering an area of 10,646.74 m², with a guaranteed operating fee of 480.27 million yuan in the first year [3] - Haisheng Pharmaceutical's invested company has initiated Phase II clinical trials for NWRD06, a novel RNA drug targeting GPC3 for liver cancer, marking a significant milestone in cancer treatment [3] - WISCO Development is planning to acquire stakes in WISCO Mining and Luzhong Mining through asset swaps and cash payments, leading to a temporary suspension of its stock [4] - Yonghui Supermarket intends to publicly sell a 28.095% stake in its subsidiary Yonghui Cloud Gold Technology [5] - Shanxi Expressway plans to acquire a 15% stake in Shanxi Transportation Industry Development Group for 74.8 million yuan [5] - China Energy Construction's subsidiary has won a 6.864 billion yuan ecological comprehensive governance project [5]

Core Viewpoint - The company, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, has received approval from the National Medical Products Administration for a supplemental application regarding the drug Cefuroxime Sodium for injection, which is a second-generation cephalosporin antibiotic with broad-spectrum efficacy against both Gram-negative and Gram-positive bacteria [1] Group 1 - The approved drug, Cefuroxime Sodium, is clinically used for treating respiratory infections, urinary tract infections, and surgical infections [1] - Cefuroxime Sodium is noted for its low renal toxicity and stability against β-lactamase, making it advantageous in clinical applications [1]

Core Viewpoint - The announcement details the establishment of two funds by the subsidiary of Baiyunshan (00874), specifically the Guangyao Guangkai Fund and the Guangyao Liwan Fund, with the first fund's partnership agreement already in effect while the second is pending signature [1] Group 1 - Baiyunshan's subsidiary, Guangyao Phase II Fund, has entered into a partnership agreement for the establishment of the Guangyao Guangkai Fund with Guangyao Capital and Guangkai Fund [1] - The partnership agreement for the Guangyao Guangkai Fund became effective on December 29, 2025, with no changes to its main terms [1] - As of the date of the announcement, the partnership agreement for the Guangyao Liwan Fund has not yet been formally signed, and the company will issue a further announcement upon its signing in accordance with Hong Kong listing rules [1]

Core Viewpoint - The announcement from Baiyunshan (00874) details the establishment of the Guangyao Guangkai Fund and the Guangyao Liwan Fund through its subsidiary, Guangyao Phase II Fund, in partnership with Guangyao Capital and Guangkai Fund [1] Group 1 - The partnership agreement for the Guangyao Guangkai Fund was signed on December 29, 2025, and became effective on the same day, with no changes to the main terms of the agreement [1] - As of the date of the announcement, the partnership agreement for the Guangyao Liwan Fund has not yet been formally signed [1] - The company will issue a further announcement in accordance with Hong Kong listing rules after the signing of the partnership agreement for the Guangyao Liwan Fund [1]

Core Viewpoint - The company Baiyunshan Pharmaceutical Group has received approval from the National Medical Products Administration for its injectable Cefuroxime Sodium, enhancing its market competitiveness [1] Group 1: Product Approval - Baiyunshan Pharmaceutical's subsidiary received a notification of approval for a supplementary application for injectable Cefuroxime Sodium [1] - The product was officially launched in China in May 2006 and submitted for consistency evaluation in April 2025 [1] Group 2: Product Characteristics - Cefuroxime Sodium is a second-generation cephalosporin effective against a wide range of Gram-negative and Gram-positive bacteria, with advantages such as a broad antibacterial spectrum, lower renal toxicity, and stability against β-lactamase [1] - It is widely used in clinical settings for treating respiratory infections, urinary tract infections, and surgical infections [1] Group 3: Market Position - Injectable Cefuroxime Sodium is included in the National Essential Medicines List (2018) and is classified as a Category B drug under the National Medical Insurance (2025) [1] - The successful completion of the consistency evaluation for the generic drug is expected to enhance the product's market competitiveness [1]

Core Viewpoint - The company has received approval for its injectable Cefuroxime Sodium from the National Medical Products Administration, enhancing its market competitiveness in the pharmaceutical sector [1] Group 1: Product Approval - The Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received the "Drug Supplement Application Approval Notice" for its injectable Cefuroxime Sodium [1] - The injectable Cefuroxime Sodium was officially launched in China in May 2006 and submitted for consistency evaluation on April 3, 2025, with acceptance received on April 11, 2025 [1] Group 2: Product Characteristics - Cefuroxime Sodium is a second-generation cephalosporin effective against most Gram-negative and Gram-positive bacteria, known for its broad antibacterial spectrum, low renal toxicity, and stability against β-lactamase [1] - The drug is widely used in clinical settings for treating respiratory infections, urinary tract infections, and surgical infections [1] Group 3: Market Position - Injectable Cefuroxime Sodium is included in the National Essential Medicines List (2018) and classified as a Category B drug under the National Medical Insurance (2025) [1] - The successful completion of the generic drug consistency evaluation is expected to enhance the market competitiveness of the product [1]

| 投资标的名称 | 广州广药广开创业投资基金合伙企业（有限 合伙） | | | --- | --- | --- | | 投资金额（万元） | 9,750 | | | 投资进展阶段 | 完成 交易要素变更 进展 | 终止 | | 特别风险提示 | 广州广药广开创业投资基金合伙企业（有限 | | | | 合伙）尚需履行工商注册登记、中国证券投 | | | | 资基金业协会登记备案等手续，实施过程尚 | | | | 存在不确定性。 | | 一、基本情况概述 2025 年 12 月 22 日，广州白云山医药集团股份有限公司（"本公司"）召 开第九届董事会第三十二次会议，审议通过了《关于广州广药二期基金股权投资 合伙企业（有限合伙）认购广州广药广开创业投资基金合伙企业（有限合伙）有 限合伙份额暨关联交易的议案》，同意本公司附属企业广州广药二期基金股权投 资合伙企业（有限合伙）（"广药二期基金"）与广州广药资本私募基金管理有 限公司（"广药资本"）、广州开发区投资基金管理有限公司（"广开基金"） 证券代码：600332 证券简称：白云山 公告编号：2025-096 广州白云山医药集团股份有限公司 关于附属企业参 ...